Last season, Dickey had a personal catcher: Josh Thole. And it wasn’t just last season. First with the Mets and then the Blue Jays, Thole backstopped Dickey’s butterflies for five seasons.
This season, Josh Thole’s in the minor leagues, at least until the Jays trade Dioner Navarro. So Wednesday night, Russell Martin got the start behind the plate.
I got to wondering about the relative importance of framing knuckleballs, and asked our friends at Baseball Info Solutions to look at some numbers. ...Read More...
The Pirates, meanwhile, are optimistic the catcher they acquired from the Yankees, Francisco Cervelli, will replicate much of what Martin offered defensively, if not his .832 OPS from 2014.
Heck, Martin probably will not match that outlier; his OPS the previous five seasons had been .702. But the Jays will be a postseason threat if they get even league-average pitching to complement their dynamic lineup. And that’s where Martin should make a difference.
Not a vote of confidence for Mike Zunino.
According to a source, the Mariners, surprisingly, were among the finalists who pushed hard for Russell Martin, who eventually agreed to a five-year, $82 million contract with the Blue Jays on Monday.
I guess the Cubs don’t have an edge on this one.
The part about the Jays signing Martin because they “have enough positions in flux” so he can move to another position is funny.
As I reported last week the Blue Jays will take a shot at signing free-agent catcher Russell Martin, who is said by some industry insiders to already be leaning in the Chicago Cubs direction. Martin wants a contract worth between $75-$80 million over five years, similar to or a little more than the deal Brian McCann received from the New York Yankees last winter. An ...
The Cubs, already the leader in free agency after landing marquee manager Joe Maddon for a $25 million, five-year deal, are going to target top free-agent catcher Russell Martin, sources connected to the team said.
Some team will get very stupid this off-season with Russell Martin.
“We’re in an interesting era for age curves because of the skew of performance-enhancing drugs,” Huntington said. “We are trying to re-evaluate aging curves because they were taken way out of whack because of the influence of performance-enhancing drugs.”
Login to Join (0 members)
Page rendered in 1.4524 seconds, 111 querie(s) executed